Shire increases maximum tender offer for Baxalta debt to $2.33B

In This List

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

11 Sep, 2018 | 00:51

Author Ravikash Bakolia
Theme Healthcare & Pharmaceuticals

Shire PLC said it increased the maximum tender amount of certain outstanding senior notes of its unit Baxalta to $2.33 billion from $2.25 billion.

Illinois-based Baxalta, Shire's wholly owned subsidiary, develops products for hemophilia, immunology and oncology.

Other terms and conditions for the tender offer remain unchanged, the Dublin-based biotechnology company said.

Citigroup Global Markets Ltd. and Morgan Stanley & Co. LLC are acting as dealer managers, with Global Bondholder Services Corp. acting as depository and information agent.